The biotech rally has been put on pause on news of the FTC lawsuit to block Amgen’s ($AMGN) acquisition of Horizon Therapeutics ($HZNP). Investors are now worried about other big M&A deals that have been announced so far in 2023. What are the implications of this move by the FTC, if any?
Level Playing Field for Smaller Bios by Slowing Big-Ticket M&A? - U…